Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Fresenius (deal terminated)
|
| gptkbp:founded |
1971
|
| gptkbp:headquartersLocation |
gptkb:Lake_Forest,_Illinois,_United_States
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:keyPerson |
gptkb:Alan_Weinstein
Douglas S. Boothe |
| gptkbp:notableEvent |
product recalls
FDA warning letters |
| gptkbp:numberOfEmployees |
over 2,000 (at peak)
|
| gptkbp:products |
generic pharmaceuticals
ophthalmic pharmaceuticals injectable pharmaceuticals |
| gptkbp:status |
filed for bankruptcy in 2020
|
| gptkbp:tradedOn |
NASDAQ: AKRX
|
| gptkbp:website |
https://www.akorn.com/
|
| gptkbp:bfsParent |
gptkb:TheraTears
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Akorn, Inc.
|